Jennifer A. Yoon primarily counsels life sciences companies on corporate and securities law.

Ms. Yoon regularly advises clients across the life sciences industry, ranging from mature public companies to early-stage companies, in corporate and financing matters, including:

  • Offerings for public companies, including initial public offerings, follow-on offerings, at-the-market offerings, and private investments in public entities
  • Securities law compliance and public company representation
  • Corporate governance and strategy for early-stage companies
  • Preferred equity financings for early-stage companies

Public Offerings and Transactions

As issuer’s counsel, Ms. Yoon represented:

  • Frequency Therapeutics in its US$84 million initial public offering of its common stock
  • Kiniksa Pharmaceuticals in its US$152 million initial public offering of its common stock
  • Momenta Pharmaceuticals in its US$230 million follow-on offering of its common stock
  • Verona Pharma in its US$79 million offering of its American Depositary Shares
  • Merus in its US$61 million initial public offering of its common shares
  • Seres Therapeutics in its US$154 million initial public offering of its common stock

As underwriters’ counsel, Ms. Yoon advised on:

  • Rubius Therapeutics in its US$227 million initial public offering of its common stock
  • Ra Pharmaceuticals in its US$105 million initial public offering of its common stock
  • Blueprint Medicines in its US$169 million initial public offering of its common stock

Public Company Representation

Ms. Yoon represents a number of domestic and foreign public companies in their securities law compliance and other public company matters, including:

  • Frequency Therapeutics
  • Kiniksa Pharmaceuticals
  • Merus
  • Seres Therapeutics
  • Verona Pharma

Early-Stage Companies

Ms. Yoon has represents a number of early-stage companies in their preferred equity financings and advises early-stage companies on corporate governance matters and strategy, including:

  • Neurogene in its US$68.5 million Series A preferred stock financing
  • Oncologie in its Series B convertible preferred share financing

Bar Qualification

  • Massachusetts

Education

  • JD, Northwestern University School of Law, 2013
  • BA, Oberlin College, 2002
    Phi Beta Kappa